We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

110 hedge funds and large institutions have $707M invested in Aclaris Therapeutics in 2017 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 16

22% more capital invested

Capital invested by funds: $579M → $707M (+$128M)

19% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 32

10% more funds holding

Funds holding: 100 → 110 (+10)

6.71% more ownership

Funds ownership: 84% → 90.71% (+6.7%)

38% less funds holding in top 10

Funds holding in top 10: 8 → 5 (-3)

Holders
110
Holders Change
+10
Holders Change %
+10%
% of All Funds
2.74%
Holding in Top 10
5
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-37.5%
% of All Funds
0.12%
New
32
Increased
38
Reduced
32
Closed
16
Calls
$3.28M
Puts
–
Net Calls
+$3.28M
Net Calls Change
+$3.28M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$34.2M
2
PC
Polar Capital
United Kingdom
+$28M
3
BlackRock
BlackRock
New York
+$22.5M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$13.3M
5
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$11.5M

Top Sellers

1
SMV
Sofinnova Management VIII
California
-$21.6M
2
Marshall Wace
Marshall Wace
United Kingdom
-$12.7M
3
RSCM
Rock Springs Capital Management
Maryland
-$12.3M
4
VC
Vivo Capital
California
-$12.3M
5
Franklin Resources
Franklin Resources
California
-$7.76M
Name Holding Trade Value Shares
Change 		Change in
Stake
TI
126
Turner Investments
Pennsylvania
– -$20K -750 Closed
2 3 4 5
6

ACRS Hedge Fund Activity: Q1 2017 in Review

110 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2017, worth a combined $707M — up 22% from $579M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new ACRS positions and 16 closed out — a net gain of 16 holders — while 38 added to existing stakes and 32 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $34.2M. The largest seller was Sofinnova Management VIII, cutting an estimated $21.6M.

  • 110 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2017, up from 100 in Q4 2016.
  • Funds reported $707M of Aclaris Therapeutics stock for Q1 2017, up 22% quarter-over-quarter.
  • 32 funds opened new Aclaris Therapeutics positions in Q1 2017 and 16 closed out, a net change of +16 holders.
  • The largest Aclaris Therapeutics buyer in Q1 2017 was Fidelity Investments, an estimated $34.2M added.
  • The largest Aclaris Therapeutics seller in Q1 2017 was Sofinnova Management VIII, an estimated $21.6M sold.

Based on aggregated 13F filings for Q1 2017.